ClinicalTrials.gg
CompletedNCT00237120Updated Nov 23, 2009

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

A Phase 3 interventional study of Imatinib in Chronic Myelogenous Leukemia in Chronic Phase, sponsored by Novartis. Completed. Open to participants aged 15 Years to 74 Years. Per ClinicalTrials.gov, last updated 2009-11-23.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
15 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
27th of 83
100 · median 60
Started
2002
with 10 others
Phase 3
14 of 93
none open now
Registered
38th of 93
by date
Lead sponsor
5 of 93
Novartis

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 27th largest by enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2002, is one of 14 in phase 3, and was the 38th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 15 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of imatinib in newly enrolled previously untreated patients with chronic phase CML.

03

Conditions studied

  • Chronic Myelogenous Leukemia in Chronic Phase

Keywords

  • Chronic Myelogenous Leukemia
  • Imatinib
  • CML
04

Who can participate

Ages eligible
15 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed as Chronic Myelogenous Leukemia in Chronic Phase
  • Previously untreated with Interferon-alpha
  • Performance status is normal or capable of only limited self-care

Exclusion criteria

Exclusion Criteria:

  • Patients who are pregnant or possibly pregnant
  • Significant hepatic diseases
  • Chronic Myelogenous Leukemia in advanced phase

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants

Interventions

06

What researchers measure

Primary outcomes

  1. 3 years overall survival

  2. Duration of remaining in chronic phase

Secondary outcomes

  1. Cytogenetic response and hematologyc response in every 3 or 6 months with 3 years treatment of Imatinib,

  2. Adverse event

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2005
First posted
Oct 12, 2005
Start
Nov 2002
CompletionActual
Jun 2007
Last update
Nov 23, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00237120
Lead sponsor
Novartis
First posted
Oct 12, 2005
Start date
Nov 2002
Completion
Jun 2007
Last update
Nov 23, 2009

Study contacts

Novartis
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion